Aerpio Pharmaceuticals, Inc.
ARPO · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $25,983 | $5,508 | $4,474 | $823 |
| % Growth | 371.7% | 23.1% | 443.6% | – |
| Cost of Goods Sold | $0 | $35,017 | $20,015 | $14,444 |
| Gross Profit | $0 | -$29,509 | -$15,541 | -$13,621 |
| % Margin | 0% | -535.7% | -347.4% | -1,655% |
| R&D Expenses | $51,030 | $35,017 | $20,015 | $14,444 |
| G&A Expenses | $0 | $7,437 | $8,281 | $7,966 |
| SG&A Expenses | $36,749 | $7,437 | $8,281 | $7,966 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5,662 | $0 | $0 | $0 |
| Operating Expenses | $93,441 | $7,437 | $7,555 | $7,960 |
| Operating Income | -$67,458 | -$36,946 | -$23,822 | -$21,587 |
| % Margin | -259.6% | -670.8% | -532.5% | -2,623% |
| Other Income/Exp. Net | $3,767 | $29 | $667 | -$594 |
| Pre-Tax Income | -$63,691 | -$36,917 | -$23,155 | -$22,181 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$63,691 | -$36,917 | -$23,155 | -$22,181 |
| % Margin | -245.1% | -670.2% | -517.5% | -2,695.1% |
| EPS | -2.36 | -1.08 | -0.96 | -1.35 |
| % Growth | -118.5% | -12.5% | 28.9% | – |
| EPS Diluted | -2.36 | -1.08 | -0.96 | -1.35 |
| Weighted Avg Shares Out | 27,030 | 34,294 | 24,104 | 16,415 |
| Weighted Avg Shares Out Dil | 27,030 | 34,294 | 24,104 | 16,415 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,925 | $29 | $59 | $600 |
| Interest Expense | -$154 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $892 | $1,169 | $1,114 |
| EBITDA | -$67,458 | -$36,054 | -$22,653 | -$20,473 |
| % Margin | -259.6% | -654.6% | -506.3% | -2,487.6% |